Do analysts recommend ALVR or ALPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALVR or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% ALPS Group Inc Ordinary Share N/A N/A N/A

Do analysts rate BOLD or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, BOLD or ALVR?

Boundless Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is BOLD or ALVR more profitable?

Boundless Bio's return on equity of -70.89% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% AlloVir N/A -71.03% -61.27%

Do analysts rate ALVR or KVAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, ALVR or KVAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is ALVR or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Keen Vision Acquisition N/A N/A N/A

Do analysts recommend ALVR or RNTX?

Rein Therapeutics has a consensus price target of $6.00, indicating a potential upside of 678.92%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, ALVR or RNTX?

Rein Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is ALVR or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Rein Therapeutics N/A N/A -63.69%

Do analysts recommend ALVR or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ALVR or EXOZ?

eXoZymes is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A eXoZymes N/A N/A -$9.16M -$1.19 N/A

Is ALVR or EXOZ more profitable?

AlloVir's return on equity of -71.03% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% eXoZymes N/A -292.15% -158.66%

AlloVir (ALVR) Competitors

$3.24 -0.01 (-0.15%)

As of 09/22/2026

Compare

ALVR vs. ALPS, BOLD, KVAC, RNTX, and EXOZ

Should you buy AlloVir stock or one of its competitors? AlloVir's main competitors and comparable companies include ALPS Group Inc Ordinary Share (ALPS), Boundless Bio (BOLD), Keen Vision Acquisition (KVAC), Rein Therapeutics (RNTX), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AlloVir compare to ALPS Group Inc Ordinary Share?

AlloVir (NASDAQ:ALVR) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled ALPS Group Inc Ordinary Share'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
ALPS Group Inc Ordinary Share	Neutral

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ALPS Group Inc Ordinary Share has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.70	-$2.01M	$0.33	1.21

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

Summary

ALPS Group Inc Ordinary Share beats AlloVir on 7 of the 10 factors compared between the two stocks.

How does AlloVir compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Boundless Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Boundless Bio's return on equity of -70.89% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
AlloVir	N/A	-71.03%	-61.27%

Boundless Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

In the previous week, Boundless Bio's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Boundless Bio	Neutral
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

66.1% of AlloVir shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Boundless Bio beats AlloVir on 5 of the 9 factors compared between the two stocks.

How does AlloVir compare to Keen Vision Acquisition?

AlloVir (NASDAQ:ALVR) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.1% of AlloVir shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Keen Vision Acquisition's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Keen Vision Acquisition	N/A	N/A	N/A

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Keen Vision Acquisition'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Keen Vision Acquisition	Neutral

Summary

Keen Vision Acquisition beats AlloVir on 4 of the 6 factors compared between the two stocks.

How does AlloVir compare to Rein Therapeutics?

AlloVir (NASDAQ:ALVR) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Rein Therapeutics has a consensus price target of $6.00, indicating a potential upside of 678.92%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Rein Therapeutics' return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Rein Therapeutics	N/A	N/A	-63.69%

Rein Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Rein Therapeutics'average media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Rein Therapeutics	Neutral

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rein Therapeutics beats AlloVir on 8 of the 11 factors compared between the two stocks.

How does AlloVir compare to eXoZymes?

AlloVir (NASDAQ:ALVR) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AlloVir's return on equity of -71.03% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
eXoZymes	N/A	-292.15%	-158.66%

eXoZymes is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
eXoZymes	N/A	N/A	-$9.16M	-$1.19	N/A

In the previous week, AlloVir's average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
eXoZymes	Neutral

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, indicating that its share price is 214% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

eXoZymes beats AlloVir on 5 of the 9 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.34M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.16	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.11	15.40	10.47	6.32
Net Income	-$190.42M	-$22.82M	$3.49B	$359.73M
7 Day Performance	1.89%	-1.70%	-0.67%	0.17%
1 Month Performance	-21.93%	-6.17%	-3.17%	-3.27%
1 Year Performance	-32.08%	30.67%	15.14%	5.58%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ALVR AlloVir	N/A	$3.24 -0.2%	N/A	-26.4%	$16.34M	N/A	N/A	110
ALPS ALPS Group Inc Ordinary Share	0.7447 of 5 stars	$0.40 -1.0%	N/A	N/A	$65.89M	$4.86M	1.20	N/A
BOLD Boundless Bio	0.8032 of 5 stars	$2.82 +0.2%	N/A	+134.8%	$64.04M	N/A	N/A	64
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
RNTX Rein Therapeutics	2.4696 of 5 stars	$0.73 +2.8%	$6.00 +725.3%	-31.2%	$62.72M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. ALPS, BOLD, KVAC, RNTX, and EXOZ

How does AlloVir compare to ALPS Group Inc Ordinary Share?

Summary

How does AlloVir compare to Boundless Bio?

Summary

How does AlloVir compare to Keen Vision Acquisition?

Summary

How does AlloVir compare to Rein Therapeutics?

Summary

How does AlloVir compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. ALPS, BOLD, KVAC, RNTX, and EXOZ

How does AlloVir compare to ALPS Group Inc Ordinary Share?

Does the media refer more to ALVR or ALPS?

Do institutionals & insiders believe in ALVR or ALPS?

Which has preferable valuation & earnings, ALVR or ALPS?

Which has more volatility & risk, ALVR or ALPS?

Do analysts recommend ALVR or ALPS?

Is ALVR or ALPS more profitable?

Summary

How does AlloVir compare to Boundless Bio?

Which has better earnings & valuation, BOLD or ALVR?

Is BOLD or ALVR more profitable?

Which has more risk & volatility, BOLD or ALVR?

Does the media prefer BOLD or ALVR?

Do analysts rate BOLD or ALVR?

Do institutionals and insiders hold more shares of BOLD or ALVR?

Summary

How does AlloVir compare to Keen Vision Acquisition?

Which has more risk and volatility, ALVR or KVAC?

Do analysts rate ALVR or KVAC?

Do institutionals & insiders have more ownership in ALVR or KVAC?

Which has better earnings & valuation, ALVR or KVAC?

Is ALVR or KVAC more profitable?

Does the media refer more to ALVR or KVAC?

Summary

How does AlloVir compare to Rein Therapeutics?

Do analysts recommend ALVR or RNTX?

Which has more risk & volatility, ALVR or RNTX?

Is ALVR or RNTX more profitable?

Which has stronger earnings & valuation, ALVR or RNTX?

Does the media favor ALVR or RNTX?

Do institutionals and insiders have more ownership in ALVR or RNTX?

Summary

How does AlloVir compare to eXoZymes?

Do insiders and institutionals have more ownership in ALVR or EXOZ?

Is ALVR or EXOZ more profitable?

Which has better earnings and valuation, ALVR or EXOZ?

Does the media favor ALVR or EXOZ?

Which has more volatility & risk, ALVR or EXOZ?

Do analysts recommend ALVR or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools